Patents Assigned to ARMAGEN, INC.
  • Publication number: 20250179201
    Abstract: Provided herein are methods and compositions for treating a subject suffering from an enzyme deficiency in the central nervous system (CNS). The bifunctional fusion antibody provided herein comprise an antibody to an endogenous blood brain barrier (BBB) receptor and an enzyme deficient in GM1 gangliosidosis or GM1. The fusion antibodies provided herein comprise galactosidase beta-1 (GLB1). The methods of treating an enzyme deficiency in the CNS comprise systemic administration of a fusion antibody provided herein.
    Type: Application
    Filed: January 28, 2025
    Publication date: June 5, 2025
    Applicant: ArmaGen, Inc.
    Inventors: William M. PARDRIDGE, Ruben J. BOADO
  • Publication number: 20240409650
    Abstract: Provided herein are methods and compositions for treating a subject suffering from an enzyme deficiency in the central nervous system (CNS). The bifunctional fusion antibody provided herein comprise an antibody to an endogenous blood brain barrier (BBB) receptor and an enzyme deficient in mucopolysaccharidosis IIIB (MPS-IIIB). The fusion antibodies provided herein comprise alpha-N-acetylgulcosaminidase (NAGLU). The methods of treating an enzyme deficiency in the CNS comprise systemic administration of a fusion antibody provided herein.
    Type: Application
    Filed: June 17, 2024
    Publication date: December 12, 2024
    Applicant: ArmaGen, Inc.
    Inventors: William M. PARDRIDGE, Ruben J. BOADO
  • Publication number: 20240335432
    Abstract: [Problem to be solved] To provide a therapeutic compound for neuronal ceroid lipofuscinosis. [Solution] Provided is a compound for treatment and/or prevention of neuronal ceroid lipofuscinosis represented by the following general formula [I]. In the general formula [I]. R1 is a methyl group or a hydroxymethyl group, R2 is a methyl group or a hydroxymethyl group, R3 is one of a hydroxy group, a methoxy group, an ethoxy group, an isopropoxy group, a methoxyethoxy group, a methoxypropoxy group, or an ethoxypolopoxy group, and R4 is one of a hydroxy group. a methoxy group, an ethoxy group, an isopropoxy group, a methoxyethoxy group, a methoxypropoxy group, or an ethoxypolopoxy group, In particular, provided is a compound represented by the general formula [I] with R1 being a methyl group, R2 being a methyl group, R3 being a hydroxy group, and R4 being a methoxyethoxy group.
    Type: Application
    Filed: September 2, 2022
    Publication date: October 10, 2024
    Applicants: JCR PHARMACEUTICALS CO., LTD., ARMAGEN, INC.
    Inventor: Mathias SCHMIDT
  • Publication number: 20240327507
    Abstract: Provided herein are methods and compositions for treating a subject suffering from a deficiency in iduronate 2-sulfatase in the CNS. The methods include systemic administration of a bifunctional fusion antibody comprising an antibody that crosses the blood brain barrier (BBB) and an iduronate 2-sulfatase.
    Type: Application
    Filed: June 11, 2024
    Publication date: October 3, 2024
    Applicant: ArmaGen, Inc.
    Inventors: William M. PARDRIDGE, Ruben J. BOADO
  • Patent number: 12043661
    Abstract: Provided herein are methods and compositions for treating a subject suffering from a deficiency in iduronate 2-sulfatase in the CNS. The methods include systemic administration of a bifunctional fusion antibody comprising an antibody that crosses the blood brain barrier (BBB) and an iduronate 2-sulfatase.
    Type: Grant
    Filed: April 30, 2021
    Date of Patent: July 23, 2024
    Assignee: ARMAGEN, INC.
    Inventors: William M. Pardridge, Ruben J. Boado
  • Patent number: 11512145
    Abstract: Provided herein are methods and compositions for treating a subject suffering from a deficiency in ?-L-Iduronidase in the CNS. The methods include systemic administration of a bifunctional fusion antibody comprising an antibody to a human insulin receptor and an ?-L-Iduronidase. A therapeutically effective systemic dose is based on the specific CNS uptake characteristics of human insulin receptor antibody-?-L-Iduronidase fusion antibodies as described herein.
    Type: Grant
    Filed: January 31, 2019
    Date of Patent: November 29, 2022
    Assignee: ARMAGEN, INC.
    Inventors: William M. Pardridge, Ruben J. Boado
  • Patent number: 11155631
    Abstract: The invention provides diagnostic and therapeutic macromolecular compositions that cross the blood-brain barrier, in some embodiments in both directions, while allowing their activity to remain substantially intact once across the barrier. Also provided are methods for using such compositions in the diagnosis or treatment of CNS disorders such as Alzheimer's disease.
    Type: Grant
    Filed: January 9, 2015
    Date of Patent: October 26, 2021
    Assignee: ARMAGEN, INC.
    Inventors: William M. Pardridge, Ruben J. Boado
  • Patent number: 11028156
    Abstract: Provided herein are methods and compositions for treating a subject suffering from a deficiency in iduronate 2-sulfatase in the CNS. The methods include systemic administration of a bifunctional fusion antibody comprising an antibody that crosses the blood brain barrier (BBB) and an iduronate 2-sulfatase.
    Type: Grant
    Filed: May 17, 2018
    Date of Patent: June 8, 2021
    Assignee: ARMAGEN, INC.
    Inventors: William M. Pardridge, Ruben J. Boado
  • Patent number: 10538589
    Abstract: Provided herein are methods and compositions for treating a subject suffering from an enzyme deficiency in the central nervous system (CNS). The bifunctional fusion antibody provided herein comprise an antibody to an endogenous blood brain barrier (BBB) receptor and an enzyme deficient in mucopolysaccharidosis IIIB (MPS-IIIB). The fusion antibodies provided herein comprise alpha-N-acetylgulcosaminidase (NAGLU). The methods of treating an enzyme deficiency in the CNS comprise systemic administration of a fusion antibody provided herein.
    Type: Grant
    Filed: January 12, 2016
    Date of Patent: January 21, 2020
    Assignee: ARMAGEN INC.
    Inventors: William M. Pardridge, Ruben J. Boado
  • Patent number: 10202467
    Abstract: Provided herein are methods and compositions for treating a subject suffering from a deficiency in ?-L-Iduronidase in the CNS. The methods include systemic administration of a bifunctional fusion antibody comprising an antibody to a human insulin receptor and an ?-L-Iduronidase. A therapeutically effective systemic dose is based on the specific CNS uptake characteristics of human insulin receptor antibody-?-L-Iduronidase fusion antibodies as described herein.
    Type: Grant
    Filed: January 3, 2017
    Date of Patent: February 12, 2019
    Assignee: ARMAGEN, INC.
    Inventors: William M. Pardridge, Ruben J. Boado
  • Patent number: 10144783
    Abstract: The invention provides diagnostic and therapeutic macromolecular compositions that cross the blood-brain barrier, in some embodiments in both directions, while allowing their activity to remain substantially intact once across the barrier. Also provided are methods for using such compositions in the diagnosis or treatment of CNS disorders such as Alzheimer's disease.
    Type: Grant
    Filed: February 27, 2014
    Date of Patent: December 4, 2018
    Assignee: ARMAGEN, INC.
    Inventors: William M. Pardridge, Ruben J. Boado
  • Patent number: 10011651
    Abstract: Provided herein are methods and compositions for treating a subject suffering from a deficiency in iduronate 2-sulfatase in the CNS. The methods include systemic administration of a bifunctional fusion antibody comprising an antibody that crosses the blood brain barrier (BBB) and an iduronate 2-sulfatase.
    Type: Grant
    Filed: June 16, 2014
    Date of Patent: July 3, 2018
    Assignee: ARMAGEN, INC.
    Inventors: William M. Pardridge, Ruben J. Boado
  • Patent number: 9975955
    Abstract: Provided herein are methods and compositions for treating a subject suffering from a deficiency in arylsulfatase A in the CNS. The methods include systemic administration of a bifunctional fusion antibody comprising an antibody to a human insulin receptor and an arylsulfatase A.
    Type: Grant
    Filed: November 11, 2014
    Date of Patent: May 22, 2018
    Assignee: ARMAGEN, INC.
    Inventors: William M. Pardridge, Ruben J. Boado